Citation Impact
Citing Papers
Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study
2008 Standout
OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
2012 Standout
Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse
2010
Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
2010 StandoutScience
Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study
2003 Standout
Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer
1999 Standout
Co-incidence of RCC-susceptibility polymorphisms with HIF cis-acting sequences supports a pathway tuning model of cancer
2019 StandoutNobel
Multidrug resistance in cancer: role of ATP–dependent transporters
2002 Standout
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
2011 Standout
Mesenchymal Transition of High-Grade Breast Carcinomas Depends on Extracellular Matrix Control of Myeloid Suppressor Cell Activity
2016
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
2015
Levels of hypoxia‐inducible factor‐1α independently predict prognosis in patients with lymph node negative breast carcinoma
2003 StandoutNobel
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Prognostic Factors in Breast Cancer
2000
Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis
2002 Standout
Ultraradical debulking of epithelial ovarian cancer with the ultrasonic surgical aspirator: A prospective randomized trial
1996
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
2015 Standout
A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: A population-based study of 4317 women diagnosed in Denmark 1978–2006
2012
Multidrug Resistance in Breast Cancer: a Meta-analysis of MDR1/gp170 Expression and Its Possible Functional Significance
1997
Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients
1996
Long-term recovery of spermatogenesis after radiotherapy in patients with testicular cancer
1990
Breast cancer
2016 Standout
Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
2013 Standout
Expression of leukemia inhibitory factor and its receptor in breast cancer: A potential autocrine and paracrine growth regulatory mechanism
1998
Poor Interobserver Reproducibility in the Diagnosis of High-grade Endometrial Carcinoma
2013
Endometriosis-Associated Ovarian Carcinoma (EAOC): An Entity Distinct from Other Ovarian Carcinomas as Suggested by a Nested Case-Control Study
2001
Adjuvant radiotherapy for stage I endometrial cancer: systematic review and meta-analysis
2007
Racial differences in the expression of cell cycle–regulatory proteins in breast carcinoma
2004
Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial
2003 Standout
Ovarian cancer
2014 Standout
TP53Mutation is an Independent Prognostic Marker for Poor Outcome in Both Node-negative and Node-positive Breast Cancer
2000
Cardiac Risks of Breast-cancer Radiotherapy: A Contemporary View
2006
Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer
2001
Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer
1998
Prognostic factors in early breast carcinoma
1994
Hyperfractionated Irradiation with or without Concurrent Chemotherapy for Locally Advanced Head and Neck Cancer
1998 Standout
Fertility Preservation in Adult Male Cancer Patients
2007
Estrogen Receptor in Primary Breast Cancer Estimated in Paraffin-embedded Tissue. A Study of its Usefulness Compared to Dextran-coated Charcoal Assay
1991
Naturally occurring B-cell responses to breast cancer
2003
New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
2018 Standout
The Role of Adjuvant Radiotherapy in Carcinoma of the Endometrium—Results in 550 Patients with Pathologic Stage I Disease
1998
Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer
2007
Immunocytochemical Analysis of Estrogen Receptors in Human Breast Carcinomas
1990
DNA damage in patients with untreated cancer as measured by the sperm chromatin structure assay
2001
Immunohistochemical analysis of estrogen receptors (ER) using formalin-fixed paraffin-embedded breast cancer tissue: Correlation with clinical endocrine response
1988
The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise
2008
Targeting multidrug resistance in cancer
2006 Standout
Tissue microarrays for high-throughput molecular profiling of tumor specimens
1998 Standout
Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: Follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial
2009
Integrated genomic characterization of endometrial carcinoma
2013 StandoutNature
Levels of Hypoxia-Inducible Factor-1 During Breast Carcinogenesis
2001 StandoutNobel
Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer
2010 Standout
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
An Analysis of Two versus Three Grades for Endometrial Carcinoma
1999
Estrogen and progesterone receptor status determined by the Ventana ES 320 automated immunohistochemical stainer and the CAS 200 image analyzer in 236 early-stage breast carcinomas: Prognostic significance
1996
Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type
2010
Biologic Significance of Quantitative Estrogen Receptor Immunohistochemical Assay by Image Analysis in Breast Cancer
1994
Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells
2011 Standout
Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial
2000 Standout
Tumour-educated macrophages promote tumour progression and metastasis
2004 Standout
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma
2004
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
Multiple-Treatments Meta-analysis of Chemotherapy and Targeted Therapies in Advanced Breast Cancer
2008
Future directions of bone-targeted therapy for metastatic breast cancer
2010
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
2012 Standout
Genes that co-cluster with estrogen receptor alpha in microarray analysis of breast biopsies
2001
Cryopreservation and semen quality in patients with Hodgkin's disease
1995
Oestrogen Receptor Analysis of Paraffin Sections and Cytosol Samples of Primary Breast Cancer in Relation to Outcome After Adjuvant Tamoxifen Treatment
1996
In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells
2003 Standout
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
2010 Standout
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
2008 Standout
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
2006 Standout
Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas
1993
Preservation of Fertility in Patients with Cancer
2009 Standout
Carboplatin versus cisplatin in solid tumors: An analysis of the literature
1998
High-Dose Platinum versus Standard Dose in Advanced Ovarian Carcinoma: A Randomized Trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC)
2000
Prognostic significance of estrogen receptors in 405 primary breast cancers: a comparison of immunohistochemical and biochemical methods
1997
Cancer of the Ovary
2004 Standout
Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.
2000
Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer
1998
Phase III Randomized Trial of 12 Versus 3 Months of Maintenance Paclitaxel in Patients With Advanced Ovarian Cancer After Complete Response to Platinum and Paclitaxel-Based Chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group Trial
2003
American Society of Clinical Oncology Recommendations on Fertility Preservation in Cancer Patients
2006 Standout
Topotecan Compared With No Therapy After Response to Surgery and Carboplatin/Paclitaxel in Patients With Ovarian Cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) Randomized Study
2004
Estrogen Receptor Null Mice: What Have We Learned and Where Will They Lead Us?
1999 Standout
American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer
2005 Standout
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
2015 Standout
Primary radiotherapy of larynx and pharynx carcinoma—An analysis of some factors influencing local control and survival
1986
Cell and Environment Interactions in Tumor Microregions: The Multicell Spheroid Model
1988 StandoutScience
Quality control in immunocytochemistry: experiences with the oestrogen receptor assay.
1992
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
2006 Standout
Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis
2006 Standout
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation
2009 Standout
Intraperitoneal treatment and dose-intense therapy in ovarian cancer
1999
Phase III Trial of Observation Versus Six Courses of Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer in Complete Response After Six Courses of Paclitaxel/Platinum-Based Chemotherapy: Final Results of the After-6 Protocol 1
2009
Divergent estrogen receptor‐positive and ‐negative breast cancer trends and etiologic heterogeneity in Denmark
2013
Works of Jørn Andersen being referenced
A Prospective Randomized Comparison of 6 and 12 Cycles of Cyclophosphamide, Adriamycin, and Cisplatin in Advanced Epithelial Ovarian Cancer: A Danish Ovarian Study Group Trial (DACOVA)
1993
Estrogen Receptor analyses in the Danish Breast Cancer Cooperative Group. History, methods, prognosis and clinical implications
2008
MIB-1 Expression in breast carcinomas with medullary features
1997
Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer
2008
Immunohistochemical estrogen receptor determination in paraffin-embedded tissue. Prediction of response to hormonal treatment in advanced breast cancer
1989
Interobserver agreement for tumour type, grade of differentiation and stage in endometrial carcinomas
1995
Molecular genetic analysis of easily accessible breast tumour DNA, purified from tissue left over from hormone receptor measurement
1998
Improved outcome from substituting methotrexate with epirubicin: Results from a randomised comparison of CMF versus CEF in patients with primary breast cancer
2007
Germ cell function and hormonal status in patients with testicular cancer
1989
Long-term survival and prognostic factors in advanced epithelial ovarian cancer with special emphasis upon the effects of protocol inclusion
1994
Prognostic factors and adjuvant treatment in early epithelial ovarian cancer
1993
Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study.
1997
The prognostic value of immunohistochemical estrogen receptor analysis in paraffin-embedded and frozen sections versus that of steroid-binding assays
1990
Relationship between radioligand binding assay, immunoenzyme assay and immunohistochemical assay for estrogen receptors in human breast cancer and association with tumor differentiation
1988
Immunocytochemical determination of the estrogen-regulated protein Mr, 24,000 in primary breast cancer and response to endocrine therapy
1989
Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: A randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C)
2008
Myocardial perfusion imaging in breast cancer patients treated with or without post-mastectomy radiotherapy
2000
[Patients with early stages of endometrial cancer should be spared adjuvant radiotherapy. Danish Endometrial Cancer Group].
1997
Carcinoma of the Larynx Series of 410 Patients Treated Primarily with60Co Irradiation
1984
Phase III Study of Intravenous Vinorelbine in Combination With Epirubicin Versus Epirubicin Alone in Patients With Advanced Breast Cancer: A Scandinavian Breast Group Trial (SBG9403)
2004
Adjuvant radiation therapy is not necessary in the management of endometrial carcinoma stage I, low-risk cases
1996